First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million First-Quarter 2021 Orphan Segment Net Sales Increased
Ask Ethan: What Does A Black Hole s Size Tell Us? forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Proactive news headlines including Horizon Minerals, archTIS, Cirralto, MGC Pharmaceuticals and Buru Energy
/EIN News/ Sydney, April 27, 2021 (GLOBE NEWSWIRE) Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
Horizon Minerals Ltd (ASX:HRZ) has received further validation of the golden potential of Boorara Gold Project, 15 kilometres east of Kalgoorlie-Boulder in the Western Australian Goldfields, with an updated independent mineral resource estimate delivering a 34% increase in grade. Click here
archTIS (ASX:AR9) recorded a successful March quarter with its overall revenue, recurring revenue and gross profit all increasing significantly. Click here
(0) TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had an ophthalmic composite outcome response
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in
The
Lancet Diabetes Endocrinology. The data further reinforce that TEPEZZA significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a long-term response. TEPEZZA the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for TED is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insu